1 completed, 1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow UCB PHARMA Inc. (US): new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Quantitative MRI for Axial Spondyloarthritis MRI - Spondylitis, Ankylosing | Terminated | The Cleveland Clinic | 1 | 2020-01-15 | 2022-08-31 | |
| This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment Brivaracetam - Epilepsy | Phase 3 | Completed | UCB PHARMA Inc. (US) | 668 | 2006-01-01 | 2021-08-17 |
Epilepsy (1) · Spondylarthritis (1) · Spondylitis, Ankylosing (1)
brivaracetam (1)
United States (2) · Australia (1) · Brazil (1) · Canada (1) · India (1) · Mexico (1)
Xiaojuan Li, PhD (1)